Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer pain study tracks how opioids impact sleep and emotions

NCT ID NCT07616648

Knowledge-focused Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 200 adults with moderate to severe cancer pain who are taking opioid painkillers like hydrocodone or oxycodone. Researchers will use smartwatches and questionnaires to track pain, sleep quality, and mood over three months. The goal is to understand how pain, insomnia, anxiety, and depression are linked, which could lead to better pain management strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better manage cancer pain by understanding how pain, sleep problems, and mood are connected.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly test a new drug or therapy. Results may not apply to all cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The subjects included patients with moderate to severe cancer pain who meet the inclusion and exclusion criteria for this study.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18-75 years. 2. Histopathologically or cytologically confirmed diagnosis of malignancy, with moderate to severe cancer-related pain (NRS ≥ 4 points), meeting the WHO three-step analgesic ladder principle, having received opioid analgesic therapy for at least one week with a stable dose and well-controlled pain. 3. ECOG performance status score ≤ 3. 4. Possess basic cognitive function and ability to complete questionnaire-based assessments and wristband-based sleep monitoring. 5. Voluntarily sign the informed consent form and agree to comply with the study follow-up procedures. Exclusion Criteria: 1. Severe cognitive impairment, history of psychiatric disorder, or language/communication barriers that precludes completion of the assessments. 2. History of opioid abuse or dependence; history of alcohol or non-opioid substance abuse. 3. Severe hepatic or renal insufficiency (Child-Pugh Class C or eGFR \< 30 mL/min). 4. Life expectancy \< 3 months. 5. Women of childbearing age without effective contraception, or who are pregnant or breastfeeding. 6. Presence of other serious diseases or special conditions that, in the investigator's judgment, may interfere with the study outcomes. 7. Presence of contraindications to the study drug, such as paralytic ileus, chronic obstructive respiratory disease, or cor pulmonale.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer Cancer Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate to severe cancer pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • First Affiliated Hospital of Zhejiang University

    RECRUITING

    Hangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.